170 related articles for article (PubMed ID: 38456511)
1. Impaired innate and adaptive immune responses to BNT162b2 SARS-CoV-2 vaccination in systemic lupus erythematosus.
Sarin KY; Zheng H; Chaichian Y; Arunachalam PS; Swaminathan G; Eschholz A; Gao F; Wirz OF; Lam B; Yang E; Lee LW; Feng A; Lewis MA; Lin J; Maecker HT; Boyd SD; Davis MM; Nadeau KC; Pulendran B; Khatri P; Utz PJ; Zaba LC
JCI Insight; 2024 Mar; 9(5):. PubMed ID: 38456511
[TBL] [Abstract][Full Text] [Related]
2. Impact of BNT162b2 mRNA anti-SARS-CoV-2 vaccine on interferon-alpha production by plasmacytoid dendritic cells and autoreactive T cells in patients with systemic lupus erythematosus: The COVALUS project.
Mageau A; Tchen J; Ferré VM; Nicaise-Roland P; Descamps D; Delory N; François C; Mendes C; Papo T; Goulenok T; Charles N; Sacré K
J Autoimmun; 2023 Jan; 134():102987. PubMed ID: 36563528
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of COVID-19 mRNA vaccination in patients with autoimmune disorders: humoral and cellular immune response.
Filippini F; Giacomelli M; Bazzani C; Fredi M; Semeraro P; Tomasi C; Franceschini F; Caruso A; Cavazzana I; Giagulli C
BMC Med; 2023 Jun; 21(1):210. PubMed ID: 37316832
[TBL] [Abstract][Full Text] [Related]
4. Rapid transient and longer-lasting innate cytokine changes associated with adaptive immunity after repeated SARS-CoV-2 BNT162b2 mRNA vaccinations.
Rosati M; Terpos E; Homan P; Bergamaschi C; Karaliota S; Ntanasis-Stathopoulos I; Devasundaram S; Bear J; Burns R; Bagratuni T; Trougakos IP; Dimopoulos MA; Pavlakis GN; Felber BK
Front Immunol; 2023; 14():1292568. PubMed ID: 38090597
[TBL] [Abstract][Full Text] [Related]
5. BNT162b2 vaccine-induced humoral and cellular responses against SARS-CoV-2 variants in systemic lupus erythematosus.
Moyon Q; Sterlin D; Miyara M; Anna F; Mathian A; Lhote R; Ghillani-Dalbin P; Breillat P; Mudumba S; de Alba S; Cohen-Aubart F; Haroche J; Pha M; Boutin THD; Chaieb H; Flores PM; Charneau P; Gorochov G; Amoura Z
Ann Rheum Dis; 2022 Apr; 81(4):575-583. PubMed ID: 34607791
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Immune Response and Disease Status in Systemic Lupus Erythematosus Patients Following SARS-CoV-2 Vaccination.
Izmirly PM; Kim MY; Samanovic M; Fernandez-Ruiz R; Ohana S; Deonaraine KK; Engel AJ; Masson M; Xie X; Cornelius AR; Herati RS; Haberman RH; Scher JU; Guttmann A; Blank RB; Plotz B; Haj-Ali M; Banbury B; Stream S; Hasan G; Ho G; Rackoff P; Blazer AD; Tseng CE; Belmont HM; Saxena A; Mulligan MJ; Clancy RM; Buyon JP
Arthritis Rheumatol; 2022 Feb; 74(2):284-294. PubMed ID: 34347939
[TBL] [Abstract][Full Text] [Related]
7. Predictors of a weak antibody response to COVID-19 mRNA vaccine in systemic lupus erythematosus.
Parsons C; Rubio J; Boulougoura A; Krishfield S; Kyttaris V
Rheumatol Int; 2023 Sep; 43(9):1621-1627. PubMed ID: 37310438
[TBL] [Abstract][Full Text] [Related]
8. Evidence of immune response to BNT162b2 COVID-19 vaccine in systemic lupus erythematosus patients treated with Belimumab.
Schiavoni I; Olivetta E; Natalucci F; Olivieri G; Lo Presti A; Fedele G; Stefanelli P; Ceccarelli F; Conti F
Lupus; 2023 Mar; 32(3):394-400. PubMed ID: 36607313
[TBL] [Abstract][Full Text] [Related]
9. Elevated CD21
Bergman P; Wullimann D; Gao Y; Wahren Borgström E; Norlin AC; Lind Enoksson S; Aleman S; Ljunggren HG; Buggert M; Smith CIE
J Clin Immunol; 2022 May; 42(4):716-727. PubMed ID: 35290571
[TBL] [Abstract][Full Text] [Related]
10. Anti-SARS-CoV-2 antibodies following vaccination are associated with lymphocyte count and serum immunoglobulins in SLE.
Reynolds JA; Faustini SE; Tosounidou S; Plant T; Ubhi M; Gilman R; Richter AG; Gordon C
Lupus; 2023 Mar; 32(3):431-437. PubMed ID: 36631440
[TBL] [Abstract][Full Text] [Related]
11. Reduced Antibodies and Innate Cytokine Changes in SARS-CoV-2 BNT162b2 mRNA Vaccinated Transplant Patients With Hematological Malignancies.
Bergamaschi C; Pagoni M; Rosati M; Angel M; Tzannou I; Vlachou M; Darmani I; Ullah A; Bear J; Devasundaram S; Burns R; Baltadakis I; Gigantes S; Dimopoulos MA; Pavlakis GN; Terpos E; Felber BK
Front Immunol; 2022; 13():899972. PubMed ID: 35693807
[TBL] [Abstract][Full Text] [Related]
12. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
Front Immunol; 2022; 13():863554. PubMed ID: 35711445
[TBL] [Abstract][Full Text] [Related]
13. Systems vaccinology of the BNT162b2 mRNA vaccine in humans.
Arunachalam PS; Scott MKD; Hagan T; Li C; Feng Y; Wimmers F; Grigoryan L; Trisal M; Edara VV; Lai L; Chang SE; Feng A; Dhingra S; Shah M; Lee AS; Chinthrajah S; Sindher SB; Mallajosyula V; Gao F; Sigal N; Kowli S; Gupta S; Pellegrini K; Tharp G; Maysel-Auslender S; Hamilton S; Aoued H; Hrusovsky K; Roskey M; Bosinger SE; Maecker HT; Boyd SD; Davis MM; Utz PJ; Suthar MS; Khatri P; Nadeau KC; Pulendran B
Nature; 2021 Aug; 596(7872):410-416. PubMed ID: 34252919
[TBL] [Abstract][Full Text] [Related]
14. Side effects and flares risk after SARS-CoV-2 vaccination in patients with systemic lupus erythematosus.
Zavala-Flores E; Salcedo-Matienzo J; Quiroz-Alva A; Berrocal-Kasay A
Clin Rheumatol; 2022 May; 41(5):1349-1357. PubMed ID: 34782941
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and safety of BNT162b2 vaccination in adolescents with systemic lupus erythematosus.
Piyaphanee N; Charuvanij S; Thepveera S; Toh ZQ; Licciardi PV; Pattaragarn A; Wongprompitak P; Boonnak K; Pheerapanyawaranun C; Chokephaibulkit K
Lupus; 2024 Apr; 33(5):450-461. PubMed ID: 38335115
[TBL] [Abstract][Full Text] [Related]
16. A 12-month follow-up study of patients with systemic lupus erythematosus after immunization against SARS-CoV-2.
Zavala-Flores E; Salcedo-Matienzo J; Huamanchumo-Guzman R; Berrocal-Kasay A; Alarcón GS
Lupus; 2024 Mar; 33(3):282-288. PubMed ID: 38237938
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial.
Oda Y; Kumagai Y; Kanai M; Iwama Y; Okura I; Minamida T; Yagi Y; Kurosawa T; Greener B; Zhang Y; Walson JL
Lancet Infect Dis; 2024 Apr; 24(4):351-360. PubMed ID: 38141632
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and risk of disease flare after a three-dose regimen with SARS-CoV-2 vaccination in patients with systemic lupus erythematosus: results from the prospective cohort study COVAC-SLE.
Larsen ES; Nilsson AC; Möller S; Voss AB; Johansen IS
Clin Exp Rheumatol; 2023 Mar; 41(3):676-684. PubMed ID: 35894059
[TBL] [Abstract][Full Text] [Related]
19. Exposure of progressive immune dysfunction by SARS-CoV-2 mRNA vaccination in patients with chronic lymphocytic leukemia: A prospective cohort study.
Qin K; Honjo K; Sherrill-Mix S; Liu W; Stoltz RM; Oman AK; Hall LA; Li R; Sterrett S; Frederick ER; Lancaster JR; Narkhede M; Mehta A; Ogunsile FJ; Patel RB; Ketas TJ; Cruz Portillo VM; Cupo A; Larimer BM; Bansal A; Goepfert PA; Hahn BH; Davis RS
PLoS Med; 2023 Jun; 20(6):e1004157. PubMed ID: 37384638
[TBL] [Abstract][Full Text] [Related]
20. Systemic IL-15, IFN-γ, and IP-10/CXCL10 signature associated with effective immune response to SARS-CoV-2 in BNT162b2 mRNA vaccine recipients.
Bergamaschi C; Terpos E; Rosati M; Angel M; Bear J; Stellas D; Karaliota S; Apostolakou F; Bagratuni T; Patseas D; Gumeni S; Trougakos IP; Dimopoulos MA; Felber BK; Pavlakis GN
Cell Rep; 2021 Aug; 36(6):109504. PubMed ID: 34352226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
